Global CDMO OXB is a global cell and gene therapy-focused CDMO with 30+ years of viral vector experience and end-to-end capabilities from development to commercialisation, signaling strong outsourcing need for sponsors seeking reliable manufacturing partners.

Viral Vector Expertise Specialization in lentivirus, AAV, adenovirus and other viral vectors, including advanced platforms like TetraVecta and dual-plasmid AAV production, presenting opportunities to convert pipeline programs into scalable manufacturing engagements.

Quality and Regulatory Robust quality assurance, analytical methods, and regulatory expertise position OXB as a trusted partner for programs requiring stringent compliance and smooth filings, reducing time to clinic and market.

Global Footprint Facilities across the UK, France and the US, plus a FTSE250/FTSE4Good listing, indicate a proven, scalable base for regional and cross-border manufacturing campaigns, enabling global supply chain resilience.

Strategic Growth Signals As a long-standing pioneer with substantial global reach and investment in viral vector tech, OXB is well-positioned to win additional development and manufacturing contracts from leading biotech and pharma clients seeking proven CDMO partnerships.